
==== Front
ACS OmegaACS OmegaaoacsodfACS Omega2470-1343American Chemical Society 3145814110.1021/acsomega.8b01930ArticleRu(II)/Ir(III)-Catalyzed C–H Bond Activation/Annulation
of Cyclic Amides with 1,3-Diketone-2-diazo Compounds: Facile Access
to 8H-Isoquinolino[1,2-b]quinazolin-8-ones and Phthalazino[2,3-a]cinnoline-8,13-diones Cai Panyuan †Zhang Enshen †Wu Yinsong Fang Taibei Li Qianqian Yang Chen Wang Jian *Shang Yongjia *Key Laboratory of Functional Molecular
Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based
Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu 241000, P.
R. China* E-mail: wang_jian989@163.com (J.W.).* E-mail: shyj@mail.ahnu.edu.cn (Y.S.).01 11 2018 30 11 2018 3 11 14575 14584 07 08 2018 19 10 2018 Copyright © 2018 American Chemical Society2018American Chemical SocietyThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

Efficient
access to 8H-isoquinolino[1,2-b]quinazolin-8-ones
and phthalazino[2,3-a]cinnoline-8,13-diones through
cyclic amide-directed Ru(II)/Ir(III)-catalyzed
C–H bond activation, has been developed. Consecutive C–H
bond activation, carbene insertion, and condensation annulation processes
were realized, affording 8H-isoquinolino[1,2-b]quinazolin-8-one and phthalazino[2,3-a]cinnoline-8,13-dione derivatives in good-to-excellent yields under
mild conditions, with H2O and N2 being generated
as the only byproducts.

document-id-old-9ao8b01930document-id-new-14ao-2018-01930accc-price
==== Body
Introduction
As poly cyclic nitrogen-containing
heterocycles, 8H-isoquinolino[1,2-b]quinazolin-8-ones and phthalazino[2,3-a]cinnoline-8,13-diones
are ubiquitous in many bioactive
synthetic compounds as well as natural products (Scheme 1). For example, compounds A and B as shown in Scheme 1 were proved to have efficient antitumor
activities.1,2 Poly cyclic nitrogen-containing heterocycles
were also commonly applied in anticonvulsant,3−5 anti-inflammatory,6 antiallergy,7,8 antimicrobial,9 cardiotonic,10 and
cell imaging11,12 research. Scaffold of 11H-pyrido[2,1-b]quinazolin-11-one H was found in many natural products13 (Scheme 1). Traditional
synthesis of such polycyclic compounds suffered from multiple steps
and harsh reaction conditions. Thus, developing general and efficient
approaches for the construction of 8H-isoquinolino[1,2-b]quinazolin-8-one and phthalazino[2,3-a]cinnoline-8,13-dione derivatives attracted a lot of efforts. For
example, Peng and Cui developed ruthenium and palladium catalyzed
directed C–H bond activation of 2-phenylquinazolin-4(3H)-ones and alkyne insertion annulations for the synthesis
of 8H-isoquinolino[1,2-b]quinazolin-8-ones,
respectively (Scheme 2).14,15 Synthesis of phthalazino[2,3-a]cinnoline-8,13-diones was independently reported by Gandhi and Perumal
via ruthenium and rhodium catalyzed alkyne insertion reactions with
2-phenyl-2,3-dihydrophthalazine-1,4-diones.16,17

Scheme 1 Representative Bioactive Molecules
Scheme 2 Transition-Metal Catalyzed C–H Activation Reactions
of 2-Phenylquinazolin-4(3H)-ones and 2-Phenyl-2,3-dihydrophthalazine-1,4-diones
Transition-metal catalyzed
C–H bond activation reactions
have been a long-term research interest of organic chemists for the
construction of new C–C and C–X (X = N, O, S et al.)
bonds because of the environmental benignity and simple operation.
As a C1 building block, carbene has attracted much attention based
on its high and diverse reaction reactivities.18−21 1,3-Diketone-2-diazo compounds
can not only react as a C1 synthon but also be used as an equivalent
of alkynes, undergoing formal C2 insertion reaction with cyclic compounds
being constructed.22 However, compared
with alkynes, 1,3-diketone-2-diazo compounds have their unique characteristics.
For instance, no additional oxidants, to which lots of substrates
cannot tolerate, were needed. Additionally, cyclic 1,3-diketone-2-diazo
compounds have their priorities because of the instability of cyclic
alkynes.23 Herein, we report facile access
to 8H-isoquinolino[1,2-b]quinazolin-8-ones
and phthalazino[2,3-a]cinnoline-8,13-diones via ruthenium
and iridium catalyzed C–H bond activation/annulation reaction
of cyclic amide derivatives. In these reactions, both cyclic and acyclic
1,3-diketone-2-diazo compounds could be transformed to corresponding
products smoothly in good to excellent yields with H2O
and N2 as the only byproducts.

Results and Discussion
The reaction was initiated with 2-(p-tolyl)quinazolin-4(3H)-one (1a) and 2-diazo-5-methylcyclohexane-1,3-dione
(2a) as model substrates with the catalysis of (RhCp*Cl2)2/AgNTf2 at 90 °C (Table 1, entry 1). To our delight,
the desired product 2,6-dimethyl-2,3-dihydro-4H-quinazolino[3,2-f]phenanthridine-4,14(1H)-dione (3a) was obtained in 58% yield. Screening of catalysts revealed
that 3 mol % of [(p-cymene)RuCl2]2 gave the best result (entries 2–5). Further investigation
of additives and solvents showed lower efficacy (entries 6–11).
In addition, no better results were found at lower or higher reaction
temperatures (80 and 100 °C).

Table 1 Optimization of Reaction
Conditionsa
entry	catalyst (mol %)	additive (30 mol %)	solvent	temp. (°C)	time (min)	yield (%)b	
1	(RhCp*Cl2)2 (3)	AgNTf2	t-BuOH	90	40	58	
2	(IrCp*Cl2)2 (3)	AgNTf2	t-BuOH	90	40	47	
3	[(p-cymene)RuCl2]2 (3)	AgNTf2	t-BuOH	90	40	73	
4	[(p-cymene)RuCl2]2 (1)	AgNTf2	t-BuOH	90	40	49	
5	[(p-cymene)RuCl2]2 (5)	AgNTf2	t-BuOH	90	40	66	
6	[(p-cymene)RuCl2]2 (3)	AgSbF6	t-BuOH	90	40	51	
7	[(p-cymene)RuCl2]2 (3)	CsOAc	t-BuOH	90	40	40	
8	[(p-cymene)RuCl2]2 (3)	AgNTf2	DMF	90	40	58	
9	[(p-cymene)RuCl2]2 (3)	AgNTf2	DCE	90	40	40	
10	[(p-cymene)RuCl2]2 (3)	AgNTf2	toluene	90	40	31	
11	[(p-cymene)RuCl2]2 (3)	AgNTf2	t-AmOH	90	40	66	
12	[(p-cymene)RuCl2]2 (3)	AgNTf2	t-BuOH	80	40	41	
13	[(p-cymene)RuCl2]2 (3)	AgNTf2	t-BuOH	100	40	29	
a Reaction conditions: 1a (0.50 mmol), 2a (0.5 mmol) in the presence
of catalyst/additive
in 5 mL of solvent under air.

b Isolated yields.

With the
optimized conditions in hand, the substrate scope of 2-phenylquinazolin-4(3H)-one derivatives were investigated first (Scheme 3). Substituents such as OMe,
OBn, Br, tBu, Cl, and OH on the aromatic
rings were well tolerated under the optimal conditions, generating
the corresponding products in moderate-to-good yields (3a–3i). It is worthy to note that the substrate
with the hydroxyl group which is intolerable under many reaction conditions
could be transformed to product 3i in an acceptable 50%
yield. When phenyl, dimethyl, or nonsubstituted cyclic diazo compounds
worked as the reactants, products 3j–3l were obtained in moderate yields. Meanwhile, heterocyclic C–H
bond activation was realized to generate 3m in 68% yield.
However, acyclic 1,3-diketone-2-diazo compounds failed to suffer the
reaction conditions.

Scheme 3 Scope of the Reaction with 2-Phenylquinazolin-4(3H)-ones
Reaction conditions: 1 (0.50 mmol), 2 (0.5 mmol), [(p-cymene)RuCl2]2 (3 mol %), AgNTf2 (30 mol %), 5 mL
of tBuOH, 90 °C. Isolated yields.

Other types of cyclic amide-directed C–H
bond activations
were further investigated with easily accessible 2-phenyl-2,3-dihydrophthalazine-1,4-dione
(4a) and 2-diazo-5,5-dimethylcyclohexane-1,3-dione (2b) as model substrates. With the above optimized catalytic
system at a higher temperature of 100 °C, 2,2-dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5a) was generated in 60% yield (Table 2, entry 1). After
optimization of the reaction conditions, the yield of 5a was increased to 93% under the condition of (IrCp*Cl2)2/AgSbF6 as catalyst in DCE at 100 °C
(entry 3).

Table 2 Optimization of Reaction Conditions
for Synthesis of 5aa
entry	catalyst (mol %)	additive (mol %)	solvent	temp. (°C)	time (h)	yield (%)b	
1	[(p-cymene)RuCl2]2 (3)	AgNTf2 (30)	t-BuOH	100	14	60	
2	(IrCp*Cl2)2 (1.5)	AgSbF6 (20)	DCE	100	14	67	
3	(IrCp*Cl2)2 (2)	AgSbF6 (20)	DCE	100	14	93	
4	(IrCp*Cl2)2 (2.5)	AgSbF6 (20)	DCE	100	14	70	
5	(IrCp*Cl2)2 (2)	AgSbF6 (10)	DCE	100	14	68	
6	(IrCp*Cl2)2 (2)	AgSbF6 (30)	DCE	100	14	56	
7	(IrCp*Cl2)2 (2.5)	AgSbF6 (20)	acetone	100	14	32	
8	(RhCp*Cl2)2 (2)	AgSbF6 (30)	THF	100	14	10	
a Reaction conditions: 1a (0.50 mmol), 4a (0.5 mmol), catalyst/additive (as indicated
in the table), 5 mL solvent, 14 h, nitrogen atmosphere.

b Isolated yields.

Next, the scope of the reaction
was investigated under the optimized
conditions (Scheme 4). Substrates with Me, tBu, F, Cl, and
Br underwent the reaction efficiently with 2-diazo-5,5-dimethylcyclohexane-1,3-dione
(2b), generating the corresponding products in good to
excellent yields (5a–5i). Steric
hindered ortho-substituted substrates could tolerate the reaction
conditions, generating 5g and 5h in 81 and
82% yields, respectively. Diverse poly cyclic heterocycles were obtained
in good yields when using monomethyl, phenyl, and nonsubstituted cyclic
diazo compounds as the reaction partners (5j–5r). It is worthy to note that five-membered-cyclic and acyclic
1,3-carbonyl-2-diazo compounds tolerated the reaction conditions,
generating the corresponding products 5s–5x in excellent yields.

Scheme 4 Scope of the Reaction with 2-Phenyl-2,3-dihydrophthalazine-1,4-diones
Reaction conditions: 4 (0.5 mmol), 2 (0.5 mmol), (IrCp*Cl2)2 (2 mol %), AgSbF6 (20 mol %), 5 mL of DCE, 100
°C. Isolated yields.

On the basis of
the reported transition-metal-catalyzed C–H
bond activation/carbene insertion reactions22,23,24 and the experiment results, a possible mechanism
was proposed in Scheme 5. An active catalytic species I was generated by ligand
exchange, which catalyzed C–H bond activation to form intermediate II. Carbene coordination and migratory insertion to intermediate II generated alkyl-ruthenium intermediate IV,
which was then protonated to intermediate V. The catalyst I was released to complete the catalytic cycle. An isomerization/intramolecular
condensation process of V took place spontaneously, affording
the compound 3.

Scheme 5 Proposed Reaction Mechanism
Conclusion
In
conclusion, we have developed an efficient and practical method
for the synthesis of 8H-isoquinolino[1,2-b]quinazolin-8-one and phthalazino[2,3-a]cinnoline-8,13-dione derivatives via ruthenium and iridium catalyzed
C–H bond activation reactions. Diverse nitrogen-containing
poly cyclic compounds were synthesized effectively under mild conditions.
The reaction proceeds through consecutive C–H bond activation,
carbene insertion, and annulation reaction with water and N2 as the only byproducts, revealing the environmental benignity of
this reaction.

Experimental Section
General Comments
Unless otherwise specified, all reagents
and starting materials were purchased from commercial sources and
used as received and the solvents were purified and dried using standard
procedures. The chromatography solvents were of technical grade and
distilled prior to use. Flash chromatography was performed using 200–300
mesh silica gel with the indicated solvent system according to standard
techniques. The 1H and 13C NMR data were recorded
on 300/500 and 75/125 MHz NMR spectrometers, unless otherwise specified.
Chemical shifts (δ) in parts per million are reported relative
to the residual signals of chloroform (7.26 ppm for 1H
and 77.16 ppm for 13C), and all 13C NMR were
recorded with proton broadband decoupling and indicated as 13C{1H} NMR. Multiplicities are described as s (singlet),
d (doublet), t (triplet), q (quartet), or m (multiplet), and the coupling
constants (J) are reported in hertz. HRMS analysis
with a quadrupole time-of-flight mass spectrometer yielded ion mass/charge
(m/z) ratios in atomic mass units.
IR spectra were measured as dry films (KBr), and the peaks are reported
in terms of wave number (cm–1).

Procedure A:
The Synthesis of 8H-Isoquinolino[1,2-b]quinazolin-8-one Derivatives 3
To
a solution of 2-(p-tolyl)quinazolin-4(3H)-one (0.5 mmol) and [(p-cymene)RuCl2]2 (3 mol %)/AgNTf2 (30 mol %) in t-BuOH (2 mL) at 90 °C was added portion wise a solution of 2-diazo-5-methylcyclohexane-1,3-dione
(0.5 mmol). After being stirred for another 40 min, the mixture was
cooled to room temperature. The reaction was quenched with water,
and the mixture was extracted with DCM three times. The combined organic
layers were dried over anhydrous Na2SO4, filtered
and concentrated in vacuo. The residue was purified by flash column
chromatography on silica gel to afford 2,6-dimethyl-2,3-dihydro-4H-quinazolino[3,2-f] phenanthridine-4,14(1H)-dione 3.

Procedure B: The Synthesis
of Phthalazino[2,3-a]cinnoline-8,13-dione Derivatives 5
A mixture
of cyclic 2-diazo-1,3-diketones 2 (0.5 mmol), 2-phenyl-2,3-dihydrophthalazine-1,4-dione 4 (0.5 mmol), [Cp*IrCl2]2 (2 mol %),
and AgSbF6 (20 mol %) in DCE (2 mL) was heated in an oil
bath at 100 °C for 14 h. Upon completion of the reaction, the
mixture was cooled to room temperature. The residue was purified by
flash column chromatography on silica gel (200–300 mesh) with
ethyl acetate and petroleum ether (1:6–1:8, v/v) as the elution
solvent to give the desired products 5.

2-Methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione
(3a)
Yellow
solid. 124 mg, 73% yield; mp: 221–223 °C; 1H NMR (500 MHz, CDCl3): δ 8.88 (s, 1H), 8.85–8.76
(m, 1H), 8.27 (d, J = 8.0 Hz, 1H), 7.86–7.77
(m, 2H), 7.47 (m, 1H), 7.40 (d, J = 8.0 Hz, 1H),
3.48 (dd, J = 18.5, 11.0 Hz, 1H), 3.37–3.18
(m, 1H), 2.80–2.77 (m, 1H), 2.53 (s, 3H), 2.49 (dd, J = 17.0, 13.0 Hz, 1H), 2.26–2.12 (br s, 1H), 1.16
(d, J = 6.5 Hz, 3H); 13C NMR (75 MHz,
CDCl3): δ 198.3, 161.6, 149.3, 147.2, 146.1, 143.9,
135.3, 129.9, 129.7, 127.2, 27.1, 126.5, 126.4, 126.2, 119.8, 118.5,
105.0, 47.1, 39.1, 30.2, 22.5, 20. 6; IR(KBr) ν: 2912, 1693,
1664, 1595, 1546, 1323, 761 cm–1; HRMS (ESI) calcd
for C22H18N2O2 [M + H]+, 343.1441; found, 343.1448.

2-Methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione
(3b)
Yellow
solid. 100 mg, 61% yield; mp: 218–220 °C; 1H NMR (300 MHz, CDCl3): δ 9.08 (d, J = 8.1 Hz, 1H), 8.97 (d, J = 7.8 Hz, 1H), 8.28 (d, J = 7.8 Hz, 1H), 7.86 (br s, 2H), 7.72 (t, J = 7.2 Hz, 1H), 7.60 (t, J = 7.2 Hz, 1H), 7.50 (dd, J = 9.6, 4.1 Hz, 1H), 3.50 (dd, J = 18.3,
10.8 Hz, 1H), 3.26 (d, J = 18.3 Hz, 1H), 2.79 (d, J = 16.8 Hz, 1H), 2.50 (dd, J = 16.5, 12.9
Hz, 1H), 2.22 (s, 1H), 1.17 (d, J = 6.3 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 198.1, 162.2,
149.8, 146.8, 146.5, 135.3, 132.6, 129.6, 128.4, 127.0, 127.0, 126.820,
126.4, 126.3, 120.1, 118.3, 47.4, 39.2, 30.0, 21.0; IR(KBr) ν:
2933, 1693, 1664, 1595, 1562, 1458, 1325, 1195, 765, 698 cm–1; HRMS (ESI) calcd for C21H16N2O2 [M + H]+, 329.1285; found, 329.1282.

6-Methoxy-2-methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione
(3c)
Yellow
solid. 94 mg, 53% yield; mp: 207–209 °C; 1H
NMR (300 MHz, C6D6): δ 9.03 (d, J = 8.7 Hz, 1H), 8.72 (s, 1H), 8.26 (d, J = 7.8 Hz, 1H), 7.95 (d, J = 7.5 Hz, 1H), 7.83 (t, J = 7.2 Hz, 1H), 7.47 (t, J = 7.5 Hz, 1H),
7.20 (d, J = 9.0 Hz, 1H), 3.98 (s, 3H), 3.51 (dd, J = 18.3, 10.8 Hz, 1H), 3.26 (d, J = 17.7
Hz, 1H), 2.79 (d, J = 16.8 Hz, 1H), 2.64–2.39
(m, 1H), 2.22 (s, 1H), 1.18 (d, J = 6.3 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 198.2, 163.7,
162.0, 150.6, 147.1, 135.5, 131.9, 129.3, 127.1, 126.1, 126.0, 119.4,
118.1, 117.7, 108.4, 55.7, 47.4, 39.4, 30.0, 21.0; IR (KBr) ν:
2964, 1691, 1666, 1595, 1544, 1363, 1379, 1319, 1026, 771 cm–1; HRMS (ESI) calcd for C22H18N2O3 [M + H]+, 359.1390; found, 359.1394.

6-Bromo-2-methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione
(3d)
Yellow
solid. 70 mg, 35% yield; mp: 215–217 °C; 1H
NMR (300 MHz, CDCl3): δ 9.30 (d, J = 1.5 Hz, 1H), 8.76 (d, J = 8.7 Hz, 1H), 8.26 (d, J = 7.8 Hz, 1H), 7.82 (q, J = 8.1 Hz, 2H),
7.66 (d, J = 8.7 Hz, 1H), 7.50 (t, J = 6.6 Hz, 1H), 3.48 (dd, J = 18.6, 10.8 Hz, 1H),
3.25 (d, J = 17.1 Hz, 1H), 2.77 (d, J = 16.5 Hz, 1H), 2.47 (dd, J = 16.8, 12.8 Hz, 1H),
2.20 (s, 1H), 1.17 (d, J = 6.3 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 197.6, 162.0, 151.2, 146.3,
146.3, 135.4, 131.7, 130.9, 129.2, 128.6, 128.1, 127.1, 127.0, 126.6,
125.6, 120.2, 117.1, 47.2, 39.3, 29.9, 21.0; IR (KBr) ν: 2953,
1703, 1666, 1585, 1546, 1394, 1319, 912, 831, 771, 698 cm–1; HRMS (ESI) calcd for C21H15BrN2O2 [M + H]+, 345.1234; found, 345.1239.

6-(Benzyloxy)-2-methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione
(3e)
Yellow
solid. 98 mg, 46% yield; mp: 208–210 °C; 1H
NMR (300 MHz, CDCl3): δ 8.90 (d, J = 8.7 Hz, 1H), 8.82 (d, J = 1.8 Hz, 1H), 8.26 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 3.6 Hz, 2H),
7.65–7.08 (m, 7H), 5.24 (s, 2H), 3.50 (dd, J = 18.3, 10.7 Hz, 1H), 3.27 (d, J = 17.7 Hz, 1H),
2.79 (d, J = 15.9 Hz, 1H), 2.64–2.35 (m, 1H),
2.21 (s, 1H), 1.17 (d, J = 6.3 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 198.3, 178.3, 162.3, 150.8,
150.1, 148.1, 146.9, 136.3, 135.2, 131.5, 129.9, 129.0, 128.6, 128.2,
127.8, 127.0, 126.7, 125.7, 119.7, 117.0, 118.86, 109.3, 103.1, 70.2,
47.4, 39.4, 29.9, 20.9; IR (KBr) ν: 2922, 1693, 1674, 1600,
1541, 1498, 1379, 1325, 1242, 1014, 886, 771, 692 cm–1; HRMS (ESI) calcd for C28H22N2O3 [M + H]+, 435.1703; found, 435.1696.

6-(tert-Butyl)-2-methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione
(3f)
Yellow solid. 85 mg, 45% yield; mp: 173–175
°C; 1H NMR (300 MHz, CDCl3): δ 9.19
(d, J = 8.4 Hz, 1H), 8.88 (d, J =
8.7 Hz, 1H), 8.28 (d, J = 7.8 Hz, 1H), 7.82 (d, J = 13.5 Hz, 2H), 7.66 (d, J = 8.5 Hz,
1H), 7.49 (d, J = 7.8 Hz, 1H), 3.50 (dd, J = 18.3, 10.6 Hz, 1H), 3.26 (d, J = 18.0
Hz, 1H), 2.79 (d, J = 14.7 Hz, 1H), 2.66–2.36
(m, 1H), 2.22 (s, 1H), 1.45 (d, J = 9.9 Hz, 9H),
1.17 (d, J = 6.4 Hz, 3); 13C NMR (75 MHz,
CDCl3): δ 198.3, 162.2, 156.4, 149.7, 146.9, 146.6,
135.2, 129.5, 127.0, 126.8, 126.2, 126.0, 124.3,122.9, 120, 118.6,
47.5, 39.2, 35.6, 31.2, 30.0, 20.9; IR (KBr) ν: 2958, 1703,
1670, 1593, 1546, 1465, 1373, 1259, 777, 729 cm–1; HRMS (ESI) calcd for C25H24rN2O2 [M + H]+, 385.1911; found, 385.1912.

12-Chloro-2-methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione
(3g)
Yellow
solid. 112 mg, 63% yield; mp: 213–215 °C; 1H NMR (300 MHz, CDCl3): δ 9.07 (d, J = 8.1 Hz, 1H), 8.89 (d, J = 7.8 Hz, 1H), 8.23 (s,
1H), 7.89–7.64 (m, 3H), 7.58 (t, J = 7.5 Hz,
1H), 3.47 (dd, J = 18.3, 10.8 Hz, 1H), 3.22 (d, J = 17.1 Hz, 1H), 2.78 (d, J = 16.5 Hz,
1H), 2.49 (dd, J = 16.5, 12.9 Hz, 1H), 2.21 (s, 1H),
1.17 (d, J = 6.3 Hz, 3H); 13C NMR (75
MHz, CDCl3): δ 198.0, 161.2, 149.5, 145.1, 135.6,
132.7, 131.8, 129.5, 128.7, 128.4, 126.9, 126.7, 126.4, 126.2, 121.0,
118.5, 47.3, 39.1, 29.9, 20.9; IR (KBr) ν: 2958, 1697, 1670,
1595, 1562, 1544, 1463, 1322, 1296, 1064, 837, 771, 690 cm–1; HRMS (ESI) calcd for C21H15Cl N2O2 [M + H]+, 363.0895; found, 363.0895.

7-Chloro-2-methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione
(3h)
Yellow
solid. 81 mg, 46% yield; mp: 220–222 °C; 1H
NMR (300 MHz, CDCl3): δ 9.09–8.74 (m, 2H),
8.27 (d, J = 7.8 Hz, 1H), 7.83 (d, J = 6.3 Hz, 2H), 7.49 (t, J = 6.3 Hz, 1H), 7.37–7.11
(m, 1H), 3.50 (dd, J = 18.3, 10.8 Hz, 1H), 3.26 (d, J = 18.3 Hz, 1H), 2.78 (d, J = 16.8 Hz,
1H), 2.60–2.35 (m, 1H), 2.21 (s, 1H), 1.17 (d, J = 6.3 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ
197.7, 162.1, 152.5, 151.3, 146.3, 135.3, 129.8, 129.7, 127.1, 126.8,
126.3, 119.9, 116.7, 116.4, 112.8, 112.5, 47.2, 39.2, 29.9, 20.9;
IR (KBr) ν: 2964, 1693, 1664, 1598, 1550, 1490, 1323, 771 cm–1; HRMS (ESI) calcd for C21H15Cl N2O2 [M + H]+, 363.0895; found,
363.0900.

8-Hydroxy-2-methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione (3i)
Yellow
solid. 85 mg, 50% yield; mp: 197–199 °C; 1H
NMR (300 MHz, CDCl3): δ 15.01 (s, 1H), 8.51 (d, J = 8.1 Hz, 1H), 8.28 (d, J = 7.8 Hz, 1H),
7.84 (t, J = 7.5 Hz, 1H), 7.70 (d, J = 8.1 Hz, 1H), 7.62 (t, J = 8.1 Hz, 1H), 7.51 (t, J = 7.5 Hz, 1H), 7.11 (d, J = 8.1 Hz, 1H),
3.44 (dd, J = 18.3, 10.8 Hz, 1H), 3.18 (d, J = 17.1 Hz, 1H), 2.78 (d, J = 16.8 Hz,
1H), 2.48 (dd, J = 16.8, 12.6 Hz, 1H), 2.20 (s, 1H),
1.17 (d, J = 6.6 Hz, 3H); 13C NMR (75
MHz, CDCl3): δ 197.5, 161.1, 152.5, 150.0, 148.6,
143.8, 135.6, 134.9, 130.2, 127.3, 126.6, 125.0, 119.8, 119.4, 116.9,
116.5, 47.4, 39.0, 29.8, 20.9; IR (KBr) ν: 3419, 2958, 1708,
1664, 1598, 1544, 14 958, 1334, 1269, 810, 758, 696 cm–1; HRMS (ESI) calcd for C21H16N2O3 [M + H]+, 345.1234; found,
345.1233.

6-(Benzyloxy)-2-phenyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione
(3j)
Yellow
solid. 111 mg, 45% yield; mp: 217–219 °C; 1H NMR (300 MHz, CDCl3): δ 9.19 (d, J = 8.4 Hz, 1H), 8.90 (s, 1H), 8.21 (d, J = 7.5 Hz,
1H), 8.08 (d, J = 7.5 Hz, 1H), 7.90–7.73 (m,
1H), 7.64–7.17 (m, 10H), 5.28 (s, 2H), 4.02 (dd, J = 18.0, 11.5 Hz, 2H), 3.70–3.22 (m, 2H), 3.22–2.83
(m, 2H); 13C NMR (125 MHz, CDCl3): δ 197.3
163.2 161.6, 149.9, 146.9, 141.9, 136.1, 135.7, 132.0, 129.7, 129.0,
128.7, 128.3, 127.8, 127.5, 127.2, 126.9, 126.2, 125.8, 119.1, 118.6,
109.5, 77.3, 77.0, 76.8, 70.4, 46.1, 40.5, 39.1; IR (KBr) ν:
2922, 1697, 1664, 1593, 1562, 1541, 1492, 1361, 1238, 1014, 771, 696
cm–1; HRMS (ESI) calcd for C33H24N2O3 [M + H]+, 497.1860; found,
497.1861.

6-(Benzyloxy)-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione (3k)
Yellow
solid. 96 mg, 46% yield; mp: 169–171 °C; 1H
NMR (300 MHz, CDCl3): δ 9.06 (d, J = 8.7 Hz, 1H), 8.82 (d, J = 2.1 Hz, 1H), 8.26 (d, J = 7.8 Hz, 1H), 7.96 (d, J = 8.1 Hz, 1H),
7.83 (t, J = 7.5 Hz, 1H), 7.44 (m, 5H), 7.27 (d, J = 7.5 Hz, 2H), 5.25 (s, 2H), 3.52 (t, J = 5.7 Hz, 2H), 2.90–2.69 (m, 2H), 2.15–1.97 (m, 2H); 13C NMR (125 MHz, CDCl3): δ 198.0, 162.7,
162.0, 151.3, 146.9, 136.2, 135.5, 129.4, 128.7, 128.3, 127.8, 127.1,
126.0, 118.2, 109.4, 105.0, 70.3, 39.5, 31.5, 22.5; IR (KBr) ν:
2933, 1693, 1660, 1550, 1367, 1301, 1236, 1010, 767, 692 cm–1; HRMS (ESI) calcd for C27H20N2O3 [M + H]+, 421.1547; found, 421.1541.

6-(Benzyloxy)-2,2-dimethyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione
(3l)
Yellow
solid. 105 mg, 47% yield; mp: 165–167 °C; 1H NMR (300 MHz, CDCl3): δ 8.94 (d, J = 8.7 Hz, 1H), 8.81 (s, 1H), 8.26 (d, J = 7.8 Hz,
1H), 7.84 (d, J = 6.9 Hz, 2H), 7.44 (m, 5H), 7.26
(s, 1H), 5.25 (s, 2H), 3.41 (s, 2H), 2.64 (s, 2H), 1.09 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 198.4, 162.5,
149.28, 146.9, 146.6, 136.3, 136.2, 135.3, 135.0, 131.4, 129.1, 128.7,
128.2, 127.8, 127.1, 126.6, 125.8, 119.8, 119.5, 118.1, 117.3, 109.50,
70.3, 52.7, 44.5, 33.2, 27.9; IR (KBr) ν: 2954, 1697, 1674,
1600, 1564, 1496, 1471, 1377, 1323, 1271, 1176, 827, 773, 729, 692
cm–1; HRMS (ESI) calcd for C29H24N2O3 [M + H]+, 449.1860; found,
449.1857.

6-Methyl-6,7-dihydro-4H-thieno[2′,3′:3,4]quinolino[2,1-b]quinazoline-4,9(5H)-dione (3m)
Yellow solid. 113 mg, 68% yield; mp: 180–182 °C; 1H NMR (300 MHz, CDCl3): δ 8.44 (d, J = 4.8 Hz, 1H), 8.28 (d, J = 7.8 Hz, 1H),
7.92–7.61 (m, 3H), 7.46 (d, J = 3.3 Hz, 1H),
3.55 (dt, J = 29.1, 13.3 Hz, 2H), 2.78 (d, J = 16.5 Hz, 1H), 2.62–2.37 (m, 1H), 2.25 (s, 1H),
1.21 (d, J = 6.3 Hz, 3H); 13C NMR (75
MHz, CDCl3): δ 196.6, 162.3, 150.8, 144.7, 135.4,
133.8, 127.3, 126.8, 126.0, 125.7, 119.4, 117.8, 46.6, 39.1, 30.1,
21.1; IR (KBr) ν: 2958, 1703, 1674, 1589, 1539, 1471, 1394,
1317, 1112, 858, 767, 692 cm–1; HRMS (ESI) calcd
for C19H14N2O2S [M + H]+, 335.0849; found, 335.0844.

2,2-Dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5a)
Yellow solid. 160 mg,
93% yield; mp: 190–192 °C; 1H NMR (500 MHz,
CDCl3): δ 8.44 (d, J = 7.7 Hz, 1H),
8.31 (d, J = 7.7 Hz, 1H),
8.25–8.21 (m, 1H), 7.96–7.91 (m, 1H), 7.91–7.86
(m, 1H), 7.80–7.76 (m, 1H), 7.32–7.26 (m, 2H), 2.89
(s, 2H), 2.50 (s, 2H), 1.13 (s, 6H); 13C NMR (125 MHz,
CDCl3): δ 196.1, 167.0, 158.2, 152.6, 135.6, 135.1,
134.4, 129.0, 126.9, 122.7, 119.8, 118.1, 52.6, 41.2, 34.2, 28.6;
IR (KBr) ν: 2975, 1691, 1669, 1599, 1379, 1298, 1248, 755, 724,
683 cm–1; HRMS (ESI) calcd for C22H18N2O3 [M + H]+, 359.1390;
found, 359.1397.

2,2,6-Trimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5b)
Yellow solid. 158 mg,
85% yield; mp: 207–209 °C; 1H NMR (500 MHz,
CDCl3): δ 8.45–8.41
(m, 1H), 8.30 (dd, J = 7.7, 0.9 Hz, 1H), 8.03 (d, J = 1.4 Hz, 1H), 7.95–7.85 (m, 2H), 7.66 (d, J = 8.4 Hz, 1H), 7.10 (dd, J = 8.4, 1.4
Hz, 1H), 2.88 (s, 2H), 2.49 (s, 2H), 2.37 (s, 3H); 13C
NMR (125 MHz, CDCl3): δ 196.2, 158.2, 157.1, 152.5,
135.1, 129.1, 129.0, 128.9, 128.3, 127.6, 122.4, 119.6, 118.1, 52.6,
41.2, 34.2, 28.5, 21.7; IR (KBr) ν: 2958, 2373, 1685, 1671,
1374, 1304, 1251, 814, 733, 689 cm–1; HRMS (ESI)
calcd for C23H20N2O3 [M
+ H]+, 373.1547; found, 373.1543.

6-(tert-Butyl)-2,2-dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5c)
Yellow solid. 155 mg,
75% yield; mp: 185–187 °C; 1H NMR (500 MHz,
CDCl3): δ 8.44 (d, J = 7.7 Hz, 1H),
8.32–8.26 (m, 2H), 7.97–7.87 (m, 2H), 7.71 (d, J = 8.7 Hz, 1H), 7.32 (dd, J = 8.7, 2.2
Hz, 1H), 2.88 (s, 2H), 2.51 (s, 2H), 1.34 (s, 9H), 1.13 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 196.4, 158.2,
157.1, 152.4, 150.0, 135.1, 134.3, 133.1, 130.3, 129.1, 129.0, 128.3,
125.5, 124.3, 122.1, 119.2, 118.3, 52.7, 41.3, 35.2, 34.3, 31.6, 28.6;
IR (KBr) ν: 2958, 2373, 1671, 1375, 1306, 1261, 1069, 687 cm–1; HRMS (ESI) calcd for C26H26N2O3 [M + H]+, 415.2016; found,
415.2022.

6-Chloro-2,2-dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5d)
Yellow solid. 157 mg,
83% yield; mp: 232–234 °C; 1H NMR (500 MHz,
CDCl3): δ 8.42 (d, J = 7.7 Hz, 1H),
8.30 (d, J = 7.6 Hz, 1H),
8.28 (d, J = 2.3 Hz, 1H), 7.97–7.87 (m, 2H),
7.70 (d, J = 8.8 Hz, 1H), 7.25–7.22 (m, 1H),
2.87 (s, 2H), 2.49 (s, 2H), 1.12 (s, 6H); 13C NMR (125
MHz, CDCl3): δ 195.7, 158.1, 157.2, 153.7, 135.3,
129.1, 129.0, 128.5, 128.2, 127.1, 124.3, 121.1, 116.9, 52.4, 41.2,
34.1, 28.5; IR (KBr) ν: 2970, 2373, 1671, 1596, 1485, 1374,
1343, 1301, 1067, 686 cm–1; HRMS (ESI) calcd for
C22H17ClN2O3 [M + H]+, 393.1000; found: 393.0991.

2,2,7-Trimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5e)
Yellow solid. 164 mg,
88% yield; mp: 160–162 °C; 1H NMR (500 MHz,
CDCl3): δ 8.45–8.39
(m, 1H), 8.32–8.25 (m, 1H), 8.13–8.07 (m, 1H), 7.95–7.83
(m, 2H), 7.60 (d, J = 1.1 Hz, 1H), 7.07 (dd, J = 8.1, 1.9 Hz, 1H), 2.86 (s, 2H), 2.48 (s, 2H), 2.33 (s,
3H), 1.11 (d, J = 1.8 Hz, 6H); 13C NMR
(125 MHz, CDCl3): δ 196.3, 158.1, 157.3, 151.7, 138.8,
135.6, 135.0, 134.3, 127.1, 120.1, 119.9, 118.3, 52.6, 41.2, 34.3,
28.6, 21.9; IR (KBr) ν: 2953, 2379, 1674, 1607, 1376, 1301,
1251, 1170, 831, 689 cm–1; HRMS (ESI) calcd for
C23H20N2O3 [M + H]+, 373.1547; found, 373.1544.

7-Bromo-2,2-dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5f)
Yellow solid. 175 mg,
80% yield; mp: 237–239 °C; 1H NMR (500 MHz,
CDCl3): δ 8.41 (dd, J = 7.7, 1.1
Hz, 1H), 8.28 (dd, J = 7.7,
1.2 Hz, 1H), 8.11 (d, J = 8.6 Hz, 1H), 7.96–7.91
(m, 2H), 7.91–7.87 (m, 1H), 7.36 (dd, J =
8.6, 2.0 Hz, 1H), 2.85 (s, 2H), 2.48 (s, 2H), 1.12 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 195.9, 185.0, 158.0, 157.3,
153.0, 136.4, 135.3, 134.7, 128.5, 121.6, 117.5, 52.5, 41.3, 34.3,
28.6; IR (KBr) ν: 2964, 2368, 1680, 1658, 1368, 1296, 1243,
1173, 1070, 686 cm–1; HRMS (ESI) calcd for C22H17BrN2O3 [M + H]+, 437.0495; found, 437.0487.

2,2,8-Trimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5g)
Yellow solid. 151 mg,
81% yield; mp: 266–268 °C; 1H NMR (500 MHz,
CDCl3): δ 8.38 (dd, J = 7.7, 1.1
Hz, 1H), 8.30 (dd, J = 7.7,
1.1 Hz, 1H), 8.08 (d, J = 7.8 Hz, 1H), 7.95–7.91
(m, 1H), 7.90–7.85 (m, 1H), 7.31–7.27 (m, 1H), 7.18
(d, J = 7.6 Hz, 1H), 3.50 (d, J =
18.2 Hz, 1H), 2.52 (d, J = 15.5 Hz, 1H), 2.40 (d, J = 15.5 Hz, 1H), 2.24 (d, J = 18.2 Hz,
1H), 2.01 (s, 3H), 1.16 (s, 3H), 1.07 (s, 3H); 13C NMR
(125 MHz, CDCl3): δ 196.1, 159.3, 157.1, 153.8, 135.5,
128.8, 128.7, 128.0, 125.5, 124.3, 122.4, 116.2, 52.4, 39.9, 33.4,
29.4, 27.9, 20.0; IR (KBr) ν: 2970, 1373, 1680, 1660, 1368,
1296, 1098, 786, 725, 686 cm–1; HRMS (ESI) calcd
for C23H20N2O3 [M + H]+, 373.1547; found, 373.1550.

8-Fluoro-2,2-dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5h)
Yellow solid. 154 mg,
82% yield; mp: 218–220 °C; 1H NMR (500 MHz,
CDCl3): δ 8.44–8.37
(m, 1H), 8.33–8.27 (m, 1H), 8.04 (d, J = 8.0
Hz, 1H), 7.97–7.85 (m, 2H), 7.35–7.27 (m, 1H), 7.12–7.03
(m, 1H), 3.52 (d, J = 18.3 Hz, 1H), 2.54 (d, J = 15.6 Hz, 1H), 2.41 (d, J = 15.6 Hz,
1H), 2.27 (d, J = 18.2 Hz, 1H), 1.17 (s, 3H), 1.07
(s, 3H); 13C NMR (125 MHz, CDCl3): δ 195.7,
157.9 (d, J = 270 Hz), 154.4 (d, J = 26.3 Hz), 152.2, 135.5, 134.4, 129.6 (d, J =
28.8 Hz), 128.9 (d, J = 7.5 Hz), 126.7, 122.4, 121.3
(d, J = 11.3 Hz), 116.4 (d, J =
18.8 Hz), 115.9, 52.3, 40.5, 33.7, 29.8, 27.5; 19F NMR
(470 MHz, CDCl3): δ −111.7; IR (KBr) ν:
2970, 2368, 1691, 1658, 1474, 1379, 1298, 795, 686 cm–1; HRMS (ESI) calcd for C22H17FN2O [M + H]+, 377.1296; found, 377.1300.

2,2-Dimethyl-2,3-dihydrobenzo[c]benzo[6,7]phthalazino[2,3-a]cinnoline-4,10,17(1H)-trione (5i)
Yellow solid. 167 mg,
82% yield; mp: 219–221 °C; 1H NMR (500 MHz,
CDCl3): δ 8.98 (s, 1H), 8.87
(s, 1H), 8.23 (dd, J = 7.7, 1.6 Hz, 1H), 8.20–8.12
(m, 2H), 7.82–7.73 (m, 3H), 7.33–7.27 (m, 2H), 2.87
(s, 2H), 2.51 (s, 2H), 1.14 (s, 6H); 13C NMR (125 MHz,
CDCl3): δ 196.1, 158.8, 158.0, 153.1, 135.8, 135.7,
135.2, 130.7, 130.1, 128.4, 127.3, 126.9, 125.5, 124.9, 123.1, 120.2,
118.1, 52.6, 41.2, 34.2, 28.4; IR (KBr) ν: 2958, 2379, 1666,
1624, 1374, 1282, 1246, 1079, 772, 750 cm–1; HRMS
(ESI) calcd for C26H20N2O3 [M + H]+, 409.1547; found, 409.1544.

2-Methyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5j)
Yellow solid. 142 mg,
82% yield; mp: 201–203 °C; 1H NMR (500 MHz,
CDCl3): δ 8.43 (dd, J = 7.3, 2.3
Hz, 1H), 8.35–8.24 (m, 2H), 7.99–7.84
(m, 2H), 7.80–7.71 (m, 1H), 7.32–7.27 (m, 1H), 7.26–7.23
(m, 1H), 2.95 (d, J = 15.0 Hz, 1H), 2.80 (d, J = 21.9 Hz, 1H), 2.73–2.61 (m, 1H), 2.35 (dd, J = 16.9, 6.7 Hz, 2H), 1.12 (s, 3H); 13C NMR
(125 MHz, CDCl3): δ 196.2, 158.2, 157.2, 154.2, 135.5,
135.2, 134.4, 129.0, 127.0, 122.9, 119.9, 47.2, 35.6, 30.4, 21.6;
IR (KBr) ν: 2958, 2925, 2368, 2340, 1685, 1674, 1320, 1297,
756, 687 cm–1; HRMS (ESI) calcd for C21H16N2O3 [M + H]+, 345.1234;
found, 345.1238.

2,6-Dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5k)
Yellow solid. 170 mg, 95% yield;
mp: 230–232 °C; 1H NMR (500 MHz, CDCl3): δ 8.41 (d, J = 7.8 Hz, 1H), 8.29 (d, J = 7.7 Hz, 1H),
8.07 (s, 1H), 7.93–7.84 (m, 2H), 7.64 (d, J = 8.4 Hz, 1H), 7.08 (d, J = 8.9 Hz, 1H), 2.93 (d, J = 18.3 Hz, 1H), 2.85–2.72 (m, 1H), 2.69–2.62
(m, 1H), 2.35 (d, J = 10.2 Hz, 5H), 1.12 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 196.3, 158.3,
157.0, 153.9, 134.3, 129.2, 129.1, 128.9, 128.4, 127.6, 122.6, 119.7,
118.5, 47.2, 35.6, 30.5, 21.8, 21.6; IR (KBr) ν: 2958, 2368,
1688, 1663, 1381, 1325, 1297, 1258, 818, 687 cm–1; HRMS (ESI) calcd for C22H18N2O3 [M + H]+, 359.1390; found, 359.1386.

6-Chloro-2-methyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5l)
Yellow solid. 153 mg,
81% yield; mp: 258–260 °C; 1H NMR (500 MHz,
CDCl3): δ 8.40 (d, J = 7.6 Hz, 1H),
8.33–8.29 (m, 2H), 7.95–7.87
(m, 2H), 7.68 (d, J = 8.8 Hz, 1H), 7.23 (dd, J = 8.8, 2.3 Hz, 1H), 2.93 (d, J = 16.8
Hz, 1H), 2.79–2.76 (m, 1H), 2.70–2.64 (m, 1H), 2.37–2.30
(m, 2H), 1.12 (d, J = 5.7 Hz, 3H); 13C
NMR (125 MHz, CDCl3): δ 195.7, 158.2, 157.2, 155.2,
134.5, 129.1, 129.0, 128.5, 128.3, 127.2, 124.5, 121.3, 117.3, 47.0,
35.7, 30.3, 21.5; IR (KBr) ν: 2953, 2362, 2340, 1688, 1669,
1318, 1293, 1240, 814 cm–1; HRMS (ESI) calcd for
C21H15ClN2O3 [M + H]+, 379.0844; found, 379.0847.

6-Bromo-2-methyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5m)
Yellow solid. 180 mg,
85% yield; mp: 246–248 °C; 1H NMR (500 MHz,
CDCl3): δ 8.47–8.29
(m, 3H), 7.95–7.87 (m, 2H), 7.65 (dd, J =
32.1, 8.8 Hz, 1H), 7.39–7.22 (m, 1H), 2.94 (d, J = 20.2 Hz, 1H), 2.86–2.73 (m, 1H), 2.73–2.61 (m, 1H),
2.42–2.29 (m, 2H), 1.11 (d, J = 5.8 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 195.7, 158.1,
157.2, 155.2, 135.3, 134.6, 129.0, 127.2, 121.5, 121.3, 46.9, 35.7,
30.3, 21.5; IR (KBr) ν: 3120, 2953, 2925, 2875, 2362, 2340,
1691, 1669, 1599, 1482, 1321, 1296, 1265, 689 cm–1; HRMS (ESI) calcd for C21H15BrN2O3 [M + H]+, 423.0339; found, 423.0334.

2,7-Dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5n)
Yellow solid. 170 mg,
95% yield; mp: 287–289 °C; 1H NMR (500 MHz,
CDCl3): δ 8.42 (d, J = 7.3 Hz, 1H),
8.30 (d, J = 7.7 Hz, 1H),
8.16 (d, J = 8.2 Hz, 1H), 7.94–7.86 (m, 2H),
7.59 (s, 1H), 7.07 (dd, J = 8.2, 0.6 Hz, 1H), 2.91
(d, J = 18.1 Hz, 1H), 2.79 (d, J = 18.3 Hz, 1H), 2.69–2.62 (m, 1H), 2.38–2.31 (m, 5H),
1.11 (d, J = 5.2 Hz, 3H); 13C NMR (125
MHz, CDCl3): δ 196.3, 158.2, 157.3, 153.2, 138.8,
134.4, 127.2, 120.2, 120.1, 118.7, 47.2, 35.6, 30.5, 21.8, 21.6; IR
(KBr) ν: 2958, 2380, 2346, 1683, 1675, 1318, 1296, 1239, 821,
688 cm–1; HRMS (ESI) calcd for C22H18N2O3 [M + H]+, 359.1390;
found, 359.1395.

7-Bromo-2-methyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5o)
Yellow solid. 171 mg,
81% yield; mp: 267–269 °C; 1H NMR (500 MHz,
CDCl3): δ 8.43–8.41
(m, 1H), 8.31 (dd, J = 7.6, 1.2 Hz, 1H), 8.18 (d, J = 8.7 Hz, 1H), 7.96–7.88 (m, 3H), 7.38 (dd, J = 8.7, 2.0 Hz, 1H), 2.91 (d, J = 18.5
Hz, 1H), 2.78 (d, J = 28.9 Hz, 1H), 2.67 (d, J = 12.2 Hz, 1H), 2.36–2.32 (m, 2H), 1.12 (d, J = 6.1 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 195.9, 158.0, 157.3, 154.5, 136.4, 135.4, 134.7, 128.5,
121.8, 117.9, 47.1, 35.7, 30.4, 21.6; IR (KBr) ν: 2964, 2368,
1677, 1315, 1296, 1229, 783, 686 cm–1; HRMS (ESI)
calcd for C21H15BrN2O3 [M + H]+, 423.0339; found, 423.0334.

2,8-Dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5p)
Yellow solid. 152 mg,
85% yield; mp: 217–219 °C; 1H NMR (500 MHz,
CDCl3): δ 8.39–8.36
(m, 1H), 8.30 (dd, J = 7.7, 0.8 Hz, 1H), 8.08 (dd, J = 18.7, 7.9 Hz, 1H), 7.93–7.91 (m, 1H), 7.88–7.85
(m, 1H), 7.30–7.27 (m, 1H), 7.17 (d, J = 7.4
Hz, 1H), 3.04 (dd, J = 17.9, 11.0 Hz, 1H), 2.69–2.60
(m, 2H), 2.40–2.34 (m, 2H), 2.01 (d, J = 7.5
Hz, 3H), 1.11 (d, J = 6.3 Hz, 3H); 13C
NMR (125 MHz, CDCl3): δ 196.4, 159.8, 159.3, 157.3,
157.2, 155.5, 155.0, 134.1, 131.9, 130.9, 128.9, 128.7, 128.0, 124.4,
117.0, 116.7, 47.2, 35.7, 27.8, 21.9, 20.1; IR (KBr) ν: 2958,
2875, 1685, 1672, 1602, 1376, 1321, 1293, 1243, 781, 683 cm–1; HRMS (ESI) calcd for C22H18N2O3 [M + H]+, 359.1390; found, 359.1397.

2-Phenyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5q)
Yellow solid. 175 mg,
86% yield; mp: 188–190 °C; 1H NMR (500 MHz,
CDCl3): δ 8.48–8.42
(m, 1H), 8.32 (dd, J = 7.6, 1.8 Hz, 1H), 8.26 (d, J = 8.1 Hz, 1H), 8.06–7.58 (m, 4H), 7.47–7.31
(m, 3H), 7.30–7.27 (m, 3H), 3.53–3.46 (m, 1H), 3.34–3.29
(m, 1H), 3.12 (d, J = 17.3 Hz, 1H), 2.96–2.86
(m, 2H); 13C NMR (125 MHz, CDCl3): δ 195.5,
158.2, 157.3, 153.8, 142.4, 135.3, 134.4, 129.3, 128.6, 128.5, 127.8,
127.5, 127.1, 126.1, 125.2, 122.8, 119.9, 45.8, 40.8, 35.3; IR (KBr)
ν: 3064, 2964, 2373, 2340, 1672, 1652, 1290, 1248, 733, 692
cm–1; HRMS (ESI) calcd for C26H18N2O3 [M + H]+, 407.1390; found,
407.1390.

6-Chloro-2-phenyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5r)
Yellow solid. 179 mg,
81% yield; mp: 186–188 °C; 1H NMR (500 MHz,
CDCl3): δ 8.40 (dd, J = 11.6, 5.0
Hz, 2H), 8.25 (d, J = 7.7
Hz, 1H), 7.95–7.91 (m, 2H), 7.71 (d, J = 8.9
Hz, 1H), 7.36–7.33 (m, 3H), 7.28–7.27 (m, 2H), 7.25
(s, 1H), 3.50–3.45 (m, 1H), 3.33–3.28 (m, 1H), 3.12
(d, J = 19.2 Hz, 1H), 2.90 (d, J = 9.5 Hz, 2H); 13C NMR (125 MHz, CDCl3): δ
195.0, 158.2, 157.2, 154.8, 142.2, 135.4, 134.6, 133.8, 132.7, 130.1,
129.3, 129.1, 128.6, 128.5, 127.9, 127.3, 127.1, 124.4, 121.3, 117.5,
45.7, 40.7, 35.4; IR (KBr) ν: 3070, 2379, 1694, 1672, 1596,
1374, 1298, 1251, 1184, 1070, 697 cm–1; HRMS (ESI)
calcd for C26H17ClN2O3 [M + H]+, 441.1000; found, 441.1005.

1H-Cyclopenta[c]phthalazino[2,3-a]cinnoline-3,9,14(2H)-trione (5s)
Yellow solid. 136 mg, 86% yield; mp: 252–254 °C; 1H NMR (500 MHz, CDCl3): δ 8.46 (m, 1H), 8.35
(dd, J = 7.8, 1.1 Hz, 1H), 8.23 (dd, J = 7.2, 2.0 Hz, 1H), 7.97–7.94 (m, 1H), 7.92–7.89 (m,
1H), 7.79–7.77 (m, 1H), 7.32–7.27 (m, 2H), 3.46–3.36
(m, 2H), 2.73–2.61 (m, 2H); 13C NMR (125 MHz, CDCl3): δ 196.1, 167.9, 165.9, 157.3, 156.4, 156.2, 153.9,
153.6, 128.5, 125.7, 123.0, 122.8, 122.7, 122.3, 122.2, 119.9, 119.8,
118.9, 118.5, 115.6, 115.4, 114.9, 114.7, 47.2, 35.6, 30.4, 21.6;
IR (KBr) ν: 3075, 2925, 2379, 2340, 1702, 1674, 1630, 1602,
1382, 1326, 1304, 1251, 1062, 692 cm–1; HRMS (ESI)
calcd for C19H12N2O3 [M
+ H]+, 317.0921; found, 317.0920.

Ethyl 6-Methyl-8,13-dioxo-8,13-dihydrophthalazino[2,3-a]cinnoline-5-carboxylate (5t)
Yellow
solid. 146 mg, 84% yield; mp: 112–114 °C; 1H NMR (500 MHz, CDCl3): δ 8.44–8.37 (m, 1H),
8.34–8.26 (m, 1H), 7.93–7.78 (m, 3H), 7.32–7.27
(mz, 1H), 7.27–7.24 (m, 1H), 7.22–7.17 (m, 1H), 4.44–4.36
(m, 2H), 2.40 (d, J = 1.5 Hz, 3H), 1.41–1.36
(m, 3H); 13C NMR (125 MHz, CDCl3): δ 166.4,
157.6, 141.2, 134.4, 128.5, 123.9, 119.9, 119.4, 62.0, 17.9, 14.6;
IR (KBr) ν: 2968, 2368, 1722, 1677, 1307, 1229, 1162, 775, 692
cm–1; HRMS (ESI) calcd for C20H16N2O4 [M + H]+, 349.1183; found,
349.1174.

Ethyl 3,6-Dimethyl-8,13-dioxo-8,13-dihydrophthalazino[2,3-a]cinnoline-5-carboxylate (5u)
Yellow
solid. 154 mg, 85% yield; mp: 154–155 °C; 1H NMR (500 MHz, CDCl3): δ 8.39 (dd, J = 7.5, 0.8 Hz, 1H), 8.29 (dd, J = 8.3, 3.0 Hz,
1H), 7.92–7.80 (m, 2H), 7.72 (dd, J = 8.3,
2.7 Hz, 1H), 7.07 (s, 2H), 4.41 (q, J = 7.1 Hz, 2H),
2.38 (s, 3H), 2.33 (s, 3H), 1.39 (t, J = 7.1 Hz,
3H); 13C NMR (125 MHz, CDCl3): δ 166.5,
157.6, 157.5, 140.5, 136.7, 134.7, 134.2, 133.2, 130.1, 129.5, 129.2,
128.7, 128.2, 125.3, 123.6, 119.7, 119.5, 61.9, 21.6, 17.9, 14.6;
IR (KBr) ν: 2981, 2932, 1733, 1659, 1607, 1319, 1232, 1177,
1047, 690 cm–1; HRMS (ESI) calcd for C21H18N2O4 [M + H]+, 363.1339;
found, 363.1334.

Ethyl 3-Chloro-6-methyl-8,13-dioxo-8,13-dihydrophthalazino[2,3-a]cinnoline-5-carboxylate (5v)
Yellow
solid. 170 mg, 89% yield; mp: 163–164 °C; 1H NMR (500 MHz, CDCl3): δ 8.39 (d, J = 7.0 Hz, 1H), 8.30 (dd, J = 7.5, 0.8 Hz, 1H),
7.94–7.84 (m, 2H), 7.76 (d, J = 8.9 Hz, 1H),
7.32 (d, J = 2.3 Hz, 1H), 7.22 (dd, J = 8.8, 2.3 Hz, 1H), 4.41 (q, J = 7.1 Hz, 2H), 2.42
(s, 3H), 1.40 (t, J = 7.1 Hz, 3H); 13C
NMR (125 MHz, CDCl3): δ 165.8, 157.7, 157.6, 142.9,
134.9, 134.6, 134.0, 132.3, 129.9, 129.5, 128.9, 128.4, 128.3, 125.5,
125.0, 121.3, 118.1, 62.2, 18.0, 14.6; IR (KBr) ν: 2992, 2365,
2338, 1717, 1671, 1385, 1328, 1224, 1058, 688 cm–1; HRMS (ESI) calcd for C20H15ClN2O4 [M + H]+, 383.0793; found, 383.0795.

Ethyl
2,6-Dimethyl-8,13-dioxo-8,13-dihydrophthalazino[2,3-a]cinnoline-5-carboxylate (5w)
Yellow
solid. 156 mg, 86% yield; mp: 122–123 °C; 1H NMR (500 MHz, CDCl3): δ 8.43–8.37 (m, 1H),
8.32–8.27 (m, 1H), 7.87 (dtd, J = 18.8, 7.4,
1.4 Hz, 2H), 7.66 (s, 1H), 7.19 (d, J = 8.0 Hz, 1H),
7.01 (dd, J = 8.0, 0.6 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 2.39 (s, 3H), 2.33 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 166.5, 157.7, 157.6, 140.2, 138.9, 135.7, 134.6, 134.4,
130.1, 129.6, 128.7, 128.2, 127.7, 124.9, 121.2, 120.1, 119.6, 61.9,
21.9, 17.8, 14.6; IR (KBr) ν: 2984, 2934, 2355, 2344, 1719,
1667, 1313, 1234, 1058, 688 cm–1; HRMS (ESI) calcd
for C21H18N2O4 [M + H]+: 363.1339; found, 363.1337.

Ethyl 2-Bromo-6-methyl-8,13-dioxo-8,13-dihydrophthalazino[2,3-a]cinnoline-5-carboxylate (5x)
Yellow
solid. 196 mg, 92% yield; mp: 182–183 °C; 1H NMR (500 MHz, CDCl3): δ 8.39 (d, J = 7.4 Hz, 1H), 8.32–8.26 (m, 1H), 8.00 (d, J = 1.7 Hz, 1H), 7.93–7.83 (m, 2H), 7.32 (dd, J = 8.5, 1.7 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 4.39
(q, J = 7.1 Hz, 2H), 2.39 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 165.9, 157.7, 157.5, 142.2, 136.6, 134.9, 134.7, 129.9,
129.8, 129.5, 128.9, 128.4, 126.4, 122.9, 122.8, 121.9, 118.7, 62.1,
18.0, 17.9, 14.6; IR (KBr) ν: 2987, 2360, 2338, 1719, 1671,
1317, 1238, 1053, 804, 690 cm–1; HRMS (ESI) calcd
for C20H15BrN2O4 [M +
H]+, 427.0288; found, 427.0293.

Supporting Information Available
The Supporting Information is
available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.8b01930.Procedures for
the preparation of starting materials
(CIF)

1H, 13C, and 19F NMR
spectra for products (CIF)

X-ray crystallography data for compounds 3a and 5a (PDF)



Supplementary Material
ao8b01930_si_001.cif

 ao8b01930_si_002.cif

 ao8b01930_si_003.pdf

 Author Contributions
† P.C. and E.Z. contributed equally.

The authors
declare no competing financial interest.

Acknowledgments
This work was supported by the National Natural
Science Foundation of China (nos. 21772001, 21702003), Natural Science
Foundation of Anhui Province (nos. 1808085MB41, 1808085QB31) and the
Start-up Research Fund of Anhui Normal University.
==== Refs
References
Khan I. ; Ibrar A. ; Ahmed W. ; Saeed A. 
Synthetic Approaches,
Functionalization and Therapeutic Potential of Quinazoline and Quinazolinone
Skeletons: The Advances Continue . Eur. J. Med.
Chem. 
2015 , 90 , 124 –169 . 10.1016/j.ejmech.2014.10.084 .25461317 
Maity A. ; Mondal S. ; Paira R. ; Hazra A. ; Naskar S. ; Sahu K. B. ; Saha P. ; Banerjee S. ; Mondal N. B. 
A Novel
Approach for the One-pot Synthesis of Linear and Angular Fused Quinazolinones . Tetrahedron Lett. 
2011 , 52 , 3033 –3037 . 10.1016/j.tetlet.2011.04.019 .
Wolfe J. F. ; Rathman T. L. ; Sleevi M. C. ; Campbell J. A. ; Greenwood T. D. 
Synthesis
and Anticonvulsant Activity of Some New 2-Substituted 3-Aryl-4(3/f)-quinazolinones . J. Med. Chem. 
1990 , 33 , 161 –166 . 10.1021/jm00163a027 .2296016 
Kornet M. J. ; Varia T. ; Beaven W. 
Synthesis
and anticonvulsant activity
of 3-amino-4(3H)-quinazolinones . J. Heterocycl.
Chem. 
1983 , 20 , 1553 –1555 . 10.1002/jhet.5570200623 .
Vaidya N. A. ; Panos C. H. ; Kite A. ; Iturrian W. B. ; Blanton C. D. Jr.
Synthesis of
3,4-Dihydro-4-oxoquinazoline Derivatives
as Potential Anticonvulsants . J. Med. Chem. 
1983 , 26 , 1422 –1425 . 10.1021/jm00364a012 .6620301 
Schwender C. F. ; Sunday B. R. ; Herzig D. J. 
11-Oxo-11 H-pyrido[2,l-b]quinazoline-8-carboxylic
Acid, an Orally Active Antiallergy Agent . J.
Med. Chem. 
1979 , 22 , 114 10.1021/jm00187a026 .423174 
de
Laszlo S. E. ; Quagliato C. S. ; Greenlee W. J. ; Patchett A. A. ; Chang R. S. L. ; Lotti V. J. ; Chen T. B. ; Scheck S. A. ; Faust K. A. 
A Potent, Orally Active, Balanced Affinity Angiotensin
II ATi Antagonist and AT2 Binding Inhibitor . J. Med. Chem. 
1993 , 36 , 3207 –3210 . 10.1021/jm00073a024 .8230109 
Lowe J. A. III; Archer R. L. ; Chapin D. S. ; Cheng J. B. ; Helweg D. ; Johnson J. L. ; Koe B. K. ; Lebel L. A. ; Moore P. F. 
Structure-Activity
Relationship of Quinazolinedione
Inhibitors of Calcium-Independent Phosphodiesterase . J. Med. Chem. 
1991 , 34 , 624 –628 . 10.1021/jm00106a024 .1995886 
Bartroli J. ; Turmo E. ; Algueró M. ; Boncompte E. ; Vericat M. L. ; Conte L. ; Ramis J. ; Merlos M. ; García-Rafanell J. ; Forn J. 
New Azole
Antifungals.
3. Synthesis and Antifungal Activity of 3-Substituted-4(3H)-quinazolinones1,2 . J. Med. Chem. 
1998 , 41 , 1869 –1882 . 10.1021/jm9707277 .9599237 
Ager I. R. ; Harrison D. R. ; Kennewell P. D. ; Taylor J. B. 
Synthesis and Central
Nervous System Activity of Quinazolones Related to 2-Methyl-3-(o-tolyl)-4(3fl)-quinazolone
(Methaqualone) . J. Med. Chem. 
1977 , 20 , 379 10.1021/jm00213a013 .845871 
Mayakrishnan S. ; Arun Y. ; Balachandran C. ; Emi N. ; Muralidharan D. ; Perumal P. T. 
Synthesis of Cinnolines via Rh(III)-catalysed Dehydrogenative
C–H/N–H Functionalization: Aggregation Induced Emission
and Cell Imaging . Org. Biomol. Chem. 
2016 , 14 , 1958 –1968 . 10.1039/c5ob02045j .26754143 
Rajkumar S. ; Savarimuthu S. A. ; Kumaran R. S. ; Nagaraja C. M. ; Gandhi T. 
Expedient
synthesis of new cinnoline diones by Ru-catalyzed Regioselective Unexpected
Deoxygenation-oxidative annulation of Propargyl Alcohols with Phthalazinones
and Pyridazinones . Chem. Commun. 
2016 , 52 , 2509 –2512 . 10.1039/c5cc09347c .
Liu J. ; Zou J. ; Yao J. ; Chen G. 
Copper-Mediated Tandem C(sp2)-H Amination
and Annulation of Arenes with 2-Aminopyridines: Synthesis of Pyrido-fused
Quinazolinone Derivatives . Adv. Synth. Catal. 
2017 , 360 , 659 –663 . 10.1002/adsc.201701286 .
Feng Y. ; Tian N. ; Li Y. ; Jia C. ; Li X. ; Wang L. ; Cui X. 
Construction of Fused Polyheterocycles
through Sequential [4 + 2] and [3 + 2] Cycloadditions . Org. Lett. 
2017 , 19 , 1658 –1661 . 10.1021/acs.orglett.7b00452 .28286958 
Lu H. ; Yang Q. ; Zhou Y. ; Guo Y. ; Deng Z. ; Ding Q. ; Peng Y. 
Cross-Coupling/Annulations
of Quinazolinones
with Alkynes for Access to Fused Polycyclic Heteroarenes under Mild
Conditions . Org. Biomol. Chem. 
2014 , 12 , 758 –764 . 10.1039/c3ob41955j .24337052 
Mayakrishnan S. ; Arun Y. ; Balachandran C. ; Emi N. ; Muralidharan D. ; Perumal P. T. 
Synthesis of cinnolines via Rh(III)-catalysed Dehydrogenative
C–H/N–H Functionalization: Aggregation Induced Emission
and Cell imaging . Org. Biomol. Chem. 
2016 , 14 , 1958 –1968 . 10.1039/c5ob02045j .26754143 
Rajkumar S. ; Savarimuthu S. A. ; Kumaran R. S. ; Nagaraja C. M. ; Gandhi T. 
Expedient
Synthesis of New Cinnolinediones by Ru-Catalyzed Regioselective Unexpected
Deoxygenation-Oxidative Annulation of Propargyl Alcohols with Phthalazinones
and Pyridazinones . Chem. Commun. 
2016 , 52 , 2509 –2512 . 10.1039/c5cc09347c .
Arockiam P. B. ; Bruneau C. ; Dixneuf P. H. 
Ruthenium(II)-Catalyzed C–H
Bond Activation and Functionalization . Chem.
Rev. 
2012 , 112 , 5879 –5918 . 10.1021/cr300153j .22934619 
Ritleng V. ; Sirlin C. ; Pfeffer M. 
Ru-, Rh-,
and Pd-Catalyzed C-C Bond
Formation Involving C–H Activation and Addition on Unsaturated
Substrates: Reactions and Mechanistic Aspects . Chem. Rev. 
2002 , 102 , 1731 –1770 . 10.1021/cr0104330 .11996548 
Ford A. ; Miel H. ; Ring A. ; Slattery C. N. ; Maguire A. R. ; McKervey M. A. 
Modern Organic Synthesis
with α-Diazocarbonyl
Compounds . Chem. Rev. 
2015 , 115 , 9981 –10080 . 10.1021/acs.chemrev.5b00121 .26284754 
Xia Y. ; Qiu D. ; Wang J. 
Transition-Metal-Catalyzed Cross-Couplings
through
Carbene Migratory Insertion . Chem. Rev. 
2017 , 117 , 13810 –13889 . 10.1021/acs.chemrev.7b00382 .29091413 
a Li S.-S. ; Xia Y.-Q. ; Hu F.-Z. ; Liu C.-F. ; Su F. ; Dong L. 
Ir(III)-Catalyzed One-Pot
Cascade Synthesis of Pentacyclic-Fused Carbazoles from Indoles and
Diazoes . Chem.—Asian J. 
2016 , 11 , 3165 –3168 . 10.1002/asia.201601197 .27643614  b Li B. ; Zhang B. ; Zhang X. ; Fan X. 
Regio-selective Synthesis
of Diversely Substituted Benzo[a]carbazoles through Rh(III)-catalyzed
Annulation of 2-Arylindoles with α-Diazo Carbonyl Compounds . Chem. Commun. 
2017 , 53 , 1297 –1300 . 10.1039/c6cc08377c . c Hu X. ; Chen X. ; Shao Y. ; Xie H. ; Deng Y. ; Ke Z. ; Jiang H. ; Zeng W. 
Co(III)-Catalyzed
Coupling-Cyclization of Aryl C–H Bonds with α-Diazoketones
Involving Wolff Rearrangement . ACS Catal. 
2018 , 8 , 1308 –1312 . 10.1021/acscatal.7b03668 . d Zhang B. ; Li B. ; Zhang X. ; Fan X. 
Synthesis
of Naphthoquinolizinones through Rh(III)-Catalyzed Double C(sp2)–H
Bond Carbenoid Insertion and Annulation of 2-Aryl-3-cyanopyridines
with α-Diazo Carbonyl Compounds . Org.
Lett. 
2017 , 19 , 2294 –2297 . 10.1021/acs.orglett.7b00839 .28437119 
a Li P. ; Xu X. ; Chen J. ; Yao H. ; Lin A. 
Rh(III)-catalyzed Synthesis of Pyrazolo[1,2-a]cinnolines
from Pyrazolidinones and Diazo compounds . Org.
Chem. Front. 
2018 , 5 , 1777 –1781 . 10.1039/c8qo00209f . b Zhou T. ; Li B. ; Wang B. 
Rhodium-catalyzed C–H
Activation of 3-(Indolin1-yl)-3-oxopropanenitriles with Diazo Compounds
and Tandem Cyclization Leading to Hydrogenated Azepino[3,2,1-hi]indoles . Chem. Commun. 
2016 , 52 , 14117 –14120 . 10.1039/c6cc07758g . c Vorobyeva D.
V. ; Vinogradov M. M. ; Nelyubina Y. V. ; Loginov D. A. ; Peregudov A. S. ; Osipov S. N. 
Rhodium(III)-catalyzed CF3-Carbenoid C–H
Functionalization of 6-Arylpurines . Org. Biomol.
Chem. 
2018 , 16 , 2966 –2974 . 10.1039/c8ob00645h .29623337  d Fang F. ; Zhang C. ; Zhou C. ; Li Y. ; Zhou Y. ; Liu H. 
Rh(III)-Catalyzed C–H Activation
of Benzoylacetonitriles and Tandem Cyclization with Diazo Compounds
to Substituted Benzo[de]chromenes . Org. Lett. 
2018 , 20 , 1720 –1724 . 10.1021/acs.orglett.8b00103 .29565597  e Liu J.-G. ; Chen W.-W. ; Gu C.-X. ; Xu B. ; Xu M.-H. 
Access to Spiroindolines and Spirodihydrobenzofurans via Pd-Catalyzed
Domino Heck Spiroyclization through C–H Activation and Carbene
Insertion . Org. Lett. 
2018 , 20 , 2728 –2732 . 10.1021/acs.orglett.8b00935 .29672066  f Zuo Y. ; He X. ; Ning Y. ; Wu Y. ; Shang Y. 
Rh(III)-Catalyzed
C–H Activation/Intramolecular Cyclization: Access to N-Acyl-2,3-dihydro-1H-carbazol-4(9H)-ones
from Cyclic 2-Diazo-1,3-diketones and N-Arylamides . ACS Omega 
2017 , 2 , 8507 –8516 . 10.1021/acsomega.7b01637 .31457387  g Yang C. ; He X. ; Zhang L. ; Han G. ; Zuo Y. ; Shang Y. 
Synthesis of Isocoumarins from Cyclic 2-Diazo-1,3-diketones
and Benzoic Acids via Rh(III)-catalyzed C–H Activation and
Esterification . J. Org. Chem. 
2017 , 82 , 2081 –2088 . 10.1021/acs.joc.6b02906 .28106400 
During the revision
of this manuscript, a similar work was online: Karishma P. ; Mahesha C. K. ; Agarwal D. S. ; Mandal S. K. ; Sakhuja R. 
Additive-Driven Rhodium-Catalyzed
[4+1]/[4+2] Annulations of N-Arylphthalazine-1,4-dione with α-Diazo
Carbonyl Compounds . J. Org. Chem. 
2018 , 83 , 11661 10.1021/acs.joc.8b01630 .30183293

